On November 12, 2025 Leukogene Therapeutics Inc., a biopharmaceutical company developing next-generation therapies for hematologic and other immunologically "cold" malignancies, reported that it has received funding from the South Carolina Research Authority (SCRA) and its investment affiliate, SC Launch Inc.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are honored to receive this strategic funding from SCRA and SC Launch Inc. It will allow us to advance our programs toward the clinic, strengthen our position as a leader in developing next-generation cancer therapeutics and continue building a world-class biotech company right here in South Carolina," said Dr. Sandeep Gupta, Chief Executive Officer of Leukogene. Nathan Dolloff, PhD, Founder and Chief Scientific Officer added, "This investment represents a strong validation of our vision and science and enables us to accelerate our mission of bringing transformative therapies to patients with hard-to-treat cancers."

"Leukogene Therapeutics exemplifies the kind of innovative, high-growth company that SCRA and SC Launch Inc. were designed to support," said Matt Bell, Executive Director of SC Launch. "Their groundbreaking immunotherapy platform and strong leadership team are well-positioned to make a lasting impact in oncology and the broader biotech sector. We are proud to partner with them as they advance toward clinical development."

(Press release, Leukogene Therapeutics, NOV 12, 2025, View Source [SID1234659861])